Merck & Co. (MRK)
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-09-04
$150.33-1.32%
Close 2026-09-04 · 1-day change
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-09-04
Broken: Primary pillar broken — Non-GAAP EPS at least $5.04 in 2026: FY26 EPS guidance $2.71 vs $5.04 target.
Merck grows revenue about 4.3% next year. Profit per share is guided near $5.10. New cancer drug approvals boost future sales. The company raised revenue and profit forecasts recently.
Legal investigations in China could hurt Merck's reputation. This may slow growth. Profit guidance is mixed despite recent raises.
The price is about 27% above our fair value near $101. Analysts expect 4% revenue growth. Our fair value is below the Street's median of $146.
Breaks if: EPS falls below $5.04 in FY26
Breaks if: Material penalties or operational disruptions from China investigations
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on expanding its oncology pipeline. The current thesis state is intact, backed by recent earnings beats and management's commitment to growth.
The market currently prices MRK at an expensive valuation compared to its peers, reflecting high expectations for future performance. There is a notable expectations gap, suggesting that while the stock is priced for growth, any missteps could lead to significant adjustments.
Fundamentals are likely to remain strong in the near term, supported by robust earnings quality and stable management. However, there is a moderate risk due to potential economic headwinds and the mixed delivery on guidance.
The thesis hinges on MRK's ability to maintain its earnings momentum and navigate potential risks from economic conditions. Additionally, the performance of sector peers like LLY, JNJ, and ABBV will be crucial for sustaining investor confidence.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports a positive outlook for MRK. Additionally, the company raised and narrowed its full-year non-GAAP EPS guidance. This reflects stronger revenue from new products and advances in its oncology pipeline.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: No significant oncology approvals or pipeline advances in 12 months
Breaks if: Revenue falls below $65.8 billion in FY26
Over the next 1 to 3 years, MRK's performance will depend on its execution and the broader healthcare sector dynamics. Not investment advice.